Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
IGF-1 LR3 vs Mecasermin (Increlex)
An educational, source-based comparison of IGF-1 LR3 and Mecasermin (Increlex) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| IGF-1 LR3 | Long-R3-IGF-I pharmacology and IGFBP interactions | Journal of Endocrinology | 2001 | Characterized extended half-life and bioactivity vs native IGF-1. |
| Mecasermin (Increlex) | Mecasermin in severe primary IGFD | JCEM | 2007 | Improved height velocity over multi-year follow-up. |
Side-effect & safety grid
- Hypoglycemia risk via insulin-receptor cross-activity.
- Not FDA-approved for human therapeutic use; banned by WADA.
- FDA-approved.
- Hypoglycemia — must be taken with food.
- Tonsillar hypertrophy, intracranial hypertension reported.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
IGF-1 LR3 vs Mecasermin (Increlex) — Key differences
- Class: IGF-1 LR3 is classified as Growth Factor, while Mecasermin (Increlex) is IGF-1 · Endocrine.
- Primary research focus: IGF-1 LR3 — muscle protein synthesis (preclinical); Mecasermin (Increlex) — severe primary igf-1 deficiency.
- Tag: Growth · Recovery vs FDA-Approved · Endocrine.